Investigational drug · Phase 2
ABBV-547
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Psoriatic Arthritis.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "ABBV-547"
First trial start
2025
Apr 11, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABBV-547", any sponsor or status.
Conditions studied
As listed on its trial records.
- Psoriatic Arthritis
Approved drugs for the same conditions: Psoriatic arthritis · Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "ABBV-547" as an intervention, largest first.
- Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic ArthritisPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06865105 · 300 participants (planned) · Start Apr 11, 2025 · Primary completion Aug 2029
Drug: Lutikizumab; Risankizumab and 2 more · For: Psoriatic Arthritis
Sites: Huntington Beach, California; Avon Park, Florida; Clearwater, Florida · 41 sites in all
- A Study to Evaluate How the Study Drug Moves Through the Body, Adverse Events, and How the Body Tolerates ABBV-547 InjectionsPivotal-lookingActive, not recruiting
AbbVieAbbVie (ABBV)
NCT07232004 · 142 participants (planned) · Start Nov 24, 2025 · Primary completion May 2028
Drug: ABBV-547; ABBV-547 Placebo · For: Healthy Volunteer; Psoriasis
Sites: Birmingham, Alabama; Bryant, Arkansas; Anaheim, California · 20 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Psoriatic Arthritis
- ZasocitinibTAK- 279, NDI-034858Phase 317 trials
Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease
- MK-7240PRA023, TulisokibartPhase 310 trials
Merck & Co. · Ulcerative Colitis, Psoriatic Arthritis, Crohn's Disease
- LutikizumabABT-981Phase 38 trials
AbbVie · Hidradenitis Suppurativa, Atopic Dermatitis, Rheumatoid Arthritis
- TQH3906Phase 34 trials
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis
- SHR-1314Phase 33 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Active Non-radiographic Axial Spondyloarthritis, Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis
- PicankibartPhase 32 trials
Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriatic Arthritis, Plaque Psoriasis
- SHR0302Phase 32 trials
Jiangsu HengRui Medicine Co., Ltd. · Non-segmental Vitiligo, Psoriatic Arthritis
- ABBV-701Phase 22 trials
AbbVie · Crohn's Disease, Ulcerative Colitis, Psoriatic Arthritis
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.